Skip to content

By continuing to use this site, you consent to our use of cookies to personalize your experience and to analyze website traffic. Learn more in our Privacy Policy.

Discover updates to RELiZORB and what they mean for your patients #

#
Upcoming Educational Programs
#

Meet the redesigned RELiZORB

Explore the updated cartridge and see what it means for your patients

RELiZORB is indicated for use in pediatric patients (ages 2 years and above) and adult patients to hydrolyze fats in enteral formula.1

RELiZORB (iMMOBILIZED lipase) cartridge
#

Use up to 6 Cartridges per Day1

For tube feeds, RELiZORB can support the use of up to 6 cartridges* in a 24-hour period, taking absorption to the next level.

#

Bolus and Continuous Feedings1

RELiZORB is compatible with both continuous and bolus feeding approaches through multiple tube-feeding setups.

#

Updated Cartridge Design1,2

The improved RELiZORB design features a new orange cap, larger iLipase microbeads, and updated filters, allowing for better formula compatibility.

#

Expanded Formula Compatibility2

RELiZORB now offers expanded formula compatibility, so patients have extensive freedom with enteral formulas. Look at the updated list here.

What has been updated?1,2

  • RELiZORB has a new look for the product and packaging, including product color
  • RELiZORB has expanded utility, including:
    • Compatibility with continuous and bolus feeding
    • Increased use of up to 6 cartridges per day
    • Expanded formula compatibility, allowing for use with some formulas with insoluble fibers

For more information about when you and your patients may expect to see the next-generation RELiZORB, please refer to the Customer Letter or the Redesigned RELiZORB FAQ Guide.

What has remained the same?

  • RELiZORB is still the only FDA-cleared enzyme product that breaks down fats in enteral formula1,3
  • The updated RELiZORB cartridge is still ENFit® compatible and connects directly to enteral-feeding tubes and supplies1
  • RELiZORB still contains iLipase®, the digestive enzyme lipase attached to small microbead carriers, which breaks down fats in enteral formulas as they pass through the cartridge, delivering absorbable fats to your patient’s body. The iLipase remains in the cartridge and is not ingested1
  • There are no changes to the safety or efficacy of RELiZORB
  • Patients currently prescribed RELiZORB will continue to receive RELiZORB from their specialty pharmacy
    • If you have any questions, please contact RELiZORB Support Services at 1-844-632-9271 or email [email protected]

*RELiZORB can be used as six 1-cartridge feeds or three 2-cartridge feeds for a maximum of 6 cartridges per day. Do not use more than 6 cartridges in a 24-hour period.1

References: 1. RELiZORB. Instructions for use. Alcresta Therapeutics, Inc; 2023. 2. RELiZORB formulas. Alcresta Therapeutics, Inc; 2023. Accessed November 28, 2023. https://relizorb.com/formulas 3. Alcresta Therapeutics announces FDA expanded use clearance for RELiZORB® (iMMOBILIZED LIPASE) Cartridge for pediatric patients ages 2 to 5 years. News release. Alcresta Therapeutics, Inc; August 31, 2023.

RELiZORB is indicated for use in pediatric patients (ages 2 years and above) and adult patients to hydrolyze fats in enteral formula.

Warnings
  • RELiZORB is for use with enteral feeding only.

RELiZORB is indicated for use in pediatric patients (ages 2 years and above) and adult patients to hydrolyze fats in enteral formula.

Warnings
  • RELiZORB is for use with enteral feeding only.
  • RELiZORB should not be connected to any intravenous (IV) line, setup, or system.
  • Medications should not be administered through the RELiZORB cartridge. Do not add medications to the enteral formula or tubing before RELiZORB. The passage of medications through RELiZORB may adversely affect the medications or the ability of RELiZORB to hydrolyze fats.
  • Fibrosing Colonopathy - Fibrosing colonopathy is a rare, serious adverse reaction associated with high-dose use of pancreatic enzyme replacement therapy in the treatment of patients with cystic fibrosis. The underlying mechanism of fibrosing colonopathy remains unknown. Patients with fibrosing colonopathy should be closely monitored because some patients may be at risk of progressing to stricture formation. RELiZORB contains lipase enzyme that is not from a porcine source. The lipase is bound to the beads, and this lipase-bead complex (iLipase) is retained within the RELiZORB cartridge. Continue to follow your physician’s guidance and porcine pancreatic enzyme labeling regarding porcine pancreatic enzyme use when used in conjunction with RELiZORB.
Cautions and Precautions
  • Do not re-use RELiZORB. RELiZORB is a single-use product. Re-use may result in contamination of the product. If re-used, RELiZORB may not effectively hydrolyze fats.
  • Do not break, alter, or place excess pressure on any part of RELiZORB. Any compromise of the structural integrity of RELiZORB may lead to improper connection to enteral feeding supplies, enteral formula leakage or risk of contamination.
  • Do not use RELiZORB after the date marked on the pouch.
  • Do not use blenderized formulas with RELiZORB. A detailed listing of enteral formulas compatible with RELiZORB can be found at www.relizorbhcp.com/compatibility.
  • RELiZORB is designed for use with enteral feeding pump systems with low flow/no flow alarms and enteral syringes for bolus syringe push. A detailed listing of formulas, pumps, and enteral feeding supplies compatible with RELiZORB can be found at www.relizorbhcp.com/compatibility.
  • Do not use excessive force when using RELiZORB with enteral syringe push feeding methods.
  • Do not rush bolus feeds. Follow guidance from your healthcare professional on how long it should take you to complete your tube feeding.
  • Ensure all inlet and outlet connectors on RELiZORB and enteral feeding supplies are clean and dry prior to making connections.
  • In order to ensure product performance, store RELiZORB in its pouch either refrigerated or at room temperature (2°C to 27°C; 36°F to 80°F).
  • RELiZORB is indicated for use with enteral feeding only; patients should follow physician’s guidance for pancreatic enzyme replacement therapy (PERT) use for meals and snacks. Patients and patient caregivers should follow physician’s guidance regarding the need for pancreatic enzyme replacement therapy (PERT) during enteral feeding.

Review full product information for RELiZORB in the Instructions for Use.